Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) EPS (Weighted Average and Diluted) (2016 - 2026)

Corvus Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 11 years, with the latest figure at -$0.15 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 15.38% to -$0.15 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.52 through Mar 2026, up 45.83% year-over-year, with the annual reading at -$0.53 for FY2025, 48.04% up from the prior year.
  • EPS (Weighted Average and Diluted) came in at -$0.15 for Q1 2026, roughly flat from -$0.15 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.07 in Q2 2024 to a low of -$0.6 in Q3 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.15 (2026), against an average of -$0.18.
  • Year-over-year, EPS (Weighted Average and Diluted) plummeted 400.0% in 2024 and then surged 80.0% in 2025.
  • Corvus Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.21 in 2022, then soared by 38.1% to -$0.13 in 2023, then decreased by 23.08% to -$0.16 in 2024, then rose by 6.25% to -$0.15 in 2025, then rose by 0.0% to -$0.15 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's EPS (Weighted Average and Diluted) are -$0.15 (Q1 2026), -$0.15 (Q4 2025), and -$0.12 (Q3 2025).